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Abstract: Supplementation with vitamins, minerals and phytonutrients may be beneficial 
for cognition, especially in older adults. The aim of this study was to assess the effects of 
multivitamin supplementation in older adults on cognitive function and associated blood 
biomarkers. In a randomised, double blind, placebo-controlled trial, healthy women (n = 68) 
and men (n = 48) aged 55–65 years were supplemented daily for 16 weeks with  
women’s and men’s formula multivitamin supplements. Assessments at baseline and  
post-supplementation included computerised cognitive tasks and blood biomarkers relevant 
to cognitive aging. No cognitive improvements were observed after supplementation with 
either formula; however, several significant improvements were observed in blood 
biomarkers including increased levels of vitamins B6 and B12 in women and men; reduced 
C-reactive protein in women; reduced homocysteine and marginally reduced oxidative stress 
in men; as well as improvements to the lipid profile in men. In healthy older people, 
multivitamin supplementation improved a number of blood biomarkers that are relevant  
to cognition, but these biomarker changes were not accompanied by improved  
cognitive function. 
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1. Introduction 
Poor nutrition is a risk factor for cognitive decline in old age [1], which suggests that addressing 
nutritional insufficiencies may improve cognitive outcomes. The various essential vitamins and minerals 
that are required in the diet to maintain general health also have many functions in the brain. These 
include roles in neuroprotection, neurotransmission, homeostatic regulation, antioxidant activities, 
energy metabolism and DNA synthesis [2]. In addition, various plant extracts have purported benefits 
to cognitive function, including Ginkgo biloba and Bacopa monnieri [3,4]. 
Minimum daily requirements for vitamins and minerals have been set by government and other 
organisations around the world [5]. However, individual requirements differ and the level required  
for sufficient reserves in the body and maintenance of optimal metabolic activity is unknown [6].  
This is particularly true for psychological function including cognitive abilities such as memory and 
attention [7]. Providing nutrients at levels above the recommended intake might therefore be beneficial, 
especially for vulnerable groups. Older adults are at increased risk of nutritional deficiency for vitamins 
including folate, vitamin B6, vitamin B12, and vitamin D; and minerals including zinc, calcium, 
magnesium; as well as decreased intake of phytonutrients [8]. 
Cognitive decline has been associated with changes in various biomarkers, some of which have been 
demonstrated to be sensitive to supplementation with nutraceuticals. Of particular interest are biomarkers 
relevant to nutritional status, which can be used to identify potential pathological processes, which 
contribute to cognitive decline. For example, high homocysteine is associated with dementia and poorer 
cognition, and is reduced by supplementation with B-group vitamins, particularly folate and B12 [9–11]. 
The inflammatory response is also associated with poorer cognition in later life, and increased 
inflammatory biomarkers are present in dementia [12,13]. Many nutrients are purported to have  
anti-inflammatory actions, including quercetin [14], vitamin D [15], and vitamin B6 [16,17]. Oxidative 
stress has been extensively studied in relation to cognitive health, with biomarkers of oxidative stress 
observed to be increased in people with cognitive decline and dementia [18]. Biomarkers of oxidative 
stress can be reduced with antioxidant vitamins [19] and plant extracts including flavonoids [20]. 
Epidemiological data have provided numerous associations between nutritional factors, associated 
biomarkers, and cognitive decline or dementia [21]. Intervention studies aiming to improve cognitive 
outcomes with supplements have had varying success, with some [22–25], but not all interventions 
yielding cognitive benefits [26,27]. Differences in supplement dose, duration and participant 
characteristics may be responsible for inconsistent findings. It is possible that nutritional supplements 
may exert maximal benefit prior to the onset of cognitive decline by addressing subtle nutritional 
deficiencies. Therefore, in supplement trials it may be useful to assess measures of nutritional status that 
also represent biomarkers of longer term poorer cognitive outcomes, especially those which may play 
an etiological role. 
Secondly, it might be advantageous to use a broad range of nutrients such as in a multivitamin.  
It is plausible that combinations of nutrients may produce stronger effects because they have the capacity 
to address diverse nutritional requirements or deficiencies that might occur between individuals. 
Combination supplements also ensure that the benefits of a given nutrient are not limited by shortage of 
another; for example, both folate and B12 are involved in homocysteine metabolism; and vitamin C can 
‘recycle’ or ‘refresh’ vitamin E [6,28]. 
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Thirdly, it is imperative that sensitive tests are selected. Tests such as the Mini Mental State 
Examination (MMSE) or the Telephone Interview for Cognitive Status (TICS), which are frequently  
used in cognitive research, might not be precise enough to pick up subtle changes in supplement  
studies [23,27]. Computerized tests that assess faculties known to decline with age would be a better 
choice due to millisecond resolution and standardization of presentation. For example, the computerized 
cognitive battery used in our previous research has been demonstrated to be sensitive to age and 
nutritional supplementation [22,29]. 
The present study aimed to address these methodological issues in a randomized, controlled trial  
of two multivitamin supplements in older adults. The primary outcome measures for cognition were 
performance on computerized cognitive tasks, in particular the Spatial Working Memory, Contextual 
Memory and Stroop Interference tasks of the computerized battery. These tasks assess abilities  
that are most susceptible to cognitive decline, including spatial functions, episodic memory, and 
inhibition/executive function [29] and performance on these tasks has been demonstrated to improve 
after nutritional supplementation including multivitamins [22,30] and flavonoids [31]. The remaining 
cognitive tasks were included as secondary outcome measures. 
Blood biomarkers were also assessed to provide information on the physiological effects of the 
supplement and to provide information regarding possible mechanisms of action. Blood biomarkers were 
considered to be secondary outcome measures. 
2. Method 
The study involved two randomised, double-blind, placebo-controlled trials, which investigated the 
effects of 16-weeks supplementation with two multivitamin, mineral and herbal supplements: a 
Women’s formula and a Men’s formula in women and men, respectively. The study was registered with 
the Australian New Zealand Clinical Trials Registry, trial ID ACTRN12608000117314. Data collection 
was carried out from August 2007 to December 2008. Ethics approval for the study was obtained from 
the Swinburne University Human Research Ethics Committee. 
2.1. Participants 
Participants were older adults aged 55 to 65 years, including 68 women and 48 men, who were healthy 
and free from any cognitive disorder. They were recruited via advertisements in local newspapers and 
seniors’ publications, noticeboards, or by word-of-mouth. Exclusion criteria included: smoking; use of 
multivitamins or combinations of vitamins or herbal supplements; self-reported history of psychological 
or neurological disorders, heart disease or stroke; and those taking blood-thinning medication (except if 
less than 100 mg aspirin). Volunteers were initially screened for the exclusion criteria via telephone and 
again on attendance at the baseline testing session. In addition, the MMSE was conducted at baseline, 
with a cut-off set at 27 from a possible score of 30 to determine eligibility into the study. All participants 
gave written informed consent. 
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2.2. Multivitamin Supplements and Placebo 
The supplements used in the study were Swisse Women’s Ultivite Multi-Vitamin, Mineral &  
Anti-Oxidant with Herbs 50+ Years™ (Women’s formula) and Swisse Men’s Ultivite Multi-Vitamin, 
Mineral & Anti-Oxidant with Herbs 50+ Years™ (Men’s formula). These multivitamins are widely 
available in Australia. Both formulas contained vitamins, minerals, plant extracts and probiotics, 
however they differed in the dosages of vitamins and there were differences in some herbal ingredients, 
which have gender-specific functions. Of particular note, only the Women’s formula contained  
Bacopa monnieri, which has putative cognition-enhancing functions [4]. A full list of ingredients is 
provided in Table 1. The placebo tablets contained starch with a small amount of vitamin B2 (riboflavin) 
to produce a similar smell and some colouration of the urine. Active and placebo tablets were identical 
in colour (Women’s formula were dark pink, Men’s formula were green) and were the same size and 
shape. Tablets were provided in blister packs; used blister packs were returned and tablets counted to 
determine compliance. 
Table 1. Ingredients of Swisse Ultivite 50+ Women’s & Men’s Formulas and Reference 
Daily Intakes (RDI) where applicable. 
Ingredient Women’s RDI Women Men’s RDI Men 
Retinyl Acetate 862.5 μg 700 μg 862.5 μg 900 μg 
D-Alpha-Tocopheryl Acid Succinate 20 mg 7 mg 25 mg 10 mg 
Thiamine Hydrochloride (vitamin B1) 30 mg 1.1 mg 35 mg 1.2 mg 
Riboflavine (vitamin B2) 30 mg 1.1 mg 35 mg 1.3 mg 
Nicotinamide (vitamin B3) 20 mg 14 mg 25 mg 16 mg 
Calcium Pantothenate (vitamin B5) 70 mg 4 mg 75 mg 6 mg 
Pyrodoxine Hydrochloride (vitamin B6) 30 mg 1.5 mg 25 mg 1.7 mg 
Cyanocobalamin (vitamin B12) 115 μg 2.4 μg 120 μg 2.4 μg 
Cholecalciferol (vitamin D3) 5 μg 10 μg 5 μg 10 μg 
Biotin (vitamin H) 150 μg 25 μg 200 μg 30 μg 
Folic Acid 500 μg 400 μg 500 μg 400 μg 
Calcium Ascorbate Dihydrate (vitamin C) 200 mg 45 mg 200 mg 45 mg 
Phytomedadione (vitamin K1) 60 μg 60 μg 70 μg 70 μg 
Calcium Orotate 100 mg 1000 mg 100 mg 1300 mg 
Magnesium Aspartate Dihydrate 100 mg 320 mg 100 mg 420 mg 
Selenomethionine 65 μg 60 μg 65 μg 70 μg 
Molybdenum Trioxide 67.5 μg 45 μg 67.5 μg 45 μg 
Chromium Picolinate 402 μg 25 μg * 402 μg 35 μg * 
Manganese Amino Acid Chelate 30 mg 5 mg 40 mg 5.5 mg 
Ferrous Fumarate 16.01 mg 8 mg 16.01 mg 8 mg 
Copper Gluconate 8.57 mg 1.2 mg * 12.14 mg 1.7 mg * 
Potassium Iodide 196 μg 
150 μg  
2800 mg * 
196 μg 
150 μg  
3800 mg * 
Zinc Amino Acid Chelate 75 mg 8 mg 100 mg 14 mg 
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Table 1. Cont. 
Ingredient Women’s  Men’s  
Lactobacillus rhamnosus 
80 million 
organisms 
 
80 million 
organisms 
 
Lactobacillus acidophilus 
80 million 
organisms 
 
80 million 
organisms 
 
Bifidobacterium longum 
35 million 
organisms 
 
35 million 
organisms 
 
Vaccinium Macrocarpon Fruit Dry 
(patented cranberry PACRAN) 
800 mg  1000 mg  
Citrus Bioflavoloids Extract 20 mg  20 mg  
Silybum Marianum Dry Fruit  
(St. Mary’s thistle) 
1500 mg  1700 mg  
Ginkgo Biloba Leaf Dry 1000 mg  1000 mg  
Crataegus Monogyna Fruit Dry (Hawthorn) 100 mg  120 mg  
Cynara Scolymus Leaf Dry  
(Globe artichoke) 
50 mg  50 mg  
Lecithin Powder—Soy Phosphatidylserine 
Enriched Soy 
10 mg  10 mg  
Scutellaria Lateriflora Herb Dry (Skullcap) 50 mg  50 mg  
Spearmint Oil 2 mg  2 mg  
Tagetes Erecta Flower Dry (Marigold) 100 mg  100 mg  
Ubidecarenone (Co-enzyme Q10)  
(from patented Ultrasome CoQ10) 
2 mg  3 mg  
Urtica Dioica Leaf Dry (Nettle) 100 mg  50 mg  
Vaccinium Myrtillus Fruit Dry (Bilberry) 100 mg  100 mg  
Vitis Vinifera Dry Seed (Grape seed) 1000 mg  1000 mg  
Bacopa Monnieri Whole Plant Dry 50 mg  -  
Cimifuga Racemosa Root & Rhizome Dry 
(Black cohosh) 
200 mg  -  
Curcuma Longa Rhizome Dry (Turmeric) 100 mg  -  
Silica Colloidal Anhydrous 20 mg  -  
Tunera Diffusa Leaf Dry (Damiana) 500 mg  -  
Withania Somnifera  
Root Dry (Ashwagandha) 
500 mg  -  
Dulacia Inopiflora  
Root Dry (Muirapuama) 
-  200 mg  
Serenoa Repens Fruit Dry (Saw palmetto) -  300 mg  
Tribulus Terrestris Fruit &  
Root Dry (Tribulus) 
-  1000 mg  
* Adequate intake where RDI values were not available. 
2.3. Sample Size Calculation and Randomisation 
Two previous studies conducted by our group, which tested nutraceutical products and used the same 
cognitive test battery, obtained moderate effect sizes, with eta-squared (η2) values of 0.484 [22] and 
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0.314 [30]. G*Power software 3.1.7 [32] was used to calculate the required sample size, using an effect 
size of 0.4, alpha of 0.05 and power of 0.80. It was determined that 52 participants were required for 
each gender for the study to have sufficient power to detect a moderate effect size. Randomisation was 
performed by Swisse Wellness Pty Ltd. (Melbourne, Vic, Australia) and was conducted in blocks of four 
with an allocation ratio of 1:1. Multivitamin and placebo tablets were provided by Swisse Wellness Pty 
Ltd. and given to the investigator in numbered packets according to the allocation schedule. Swisse 
Wellness Pty Ltd. held the allocation schedule until data collection was completed, thus all investigators 
were blind to allocation for the duration of data collection. Numbers were allocated sequentially as 
participants were enrolled in the study. 
2.4. Measures and Procedures 
Participants in both trials followed the same protocol. They were assessed on a range of demographic 
measures, cognitive performance tasks, blood biomarkers, and cardiovascular measures (cardiovascular 
results to be reported separately). Demographic measures included date of birth, number of years of 
education, body mass index, and details of medication or supplement use. 
Cognitive testing comprised two equivalent versions of a battery of eight computerized cognitive 
tests, which took approximately 45 min to complete. Responses were made on a response box with  
four coloured buttons arranged in the positions of compass poles as follows: top/yellow, bottom/green, 
left/blue/no, and right/red/yes. The tasks included in the battery were: Simple Reaction Time (fast 
response to presentation of a white square); Choice Reaction Time (blue/red response to a blue triangle 
or red square), Immediate and Delayed Recognition Memory (for abstract images, yes/no response), 
Stroop Congruent (red/yellow/green/blue response to the colour of the word, with matching text),  
Stroop Incongruent (red/yellow/green/blue response to colour of the word, with non-matching text), 
Spatial Working Memory (yes/no response to location of white squares in a grid) and Contextual 
Memory (top/bottom/left/right response to indicate original location of previously presented everyday 
items). The cognitive battery has been described in detail elsewhere [22]. 
Blood biomarkers were assessed using a commercial pathology company. Tests included whole blood 
pyridoxal 5’-phosphate (vitamin B6); serum vitamin B12; red cell folate; serum homocysteine; serum 
high-sensitivity C-reactive protein (CRP); whole blood fibrinogen; plasma protein carbonyls; full lipid 
profile including total cholesterol, HDL, LDL and triglycerides; kidney and liver function tests including 
aspartate transaminase (AST) and alanine transaminase (ALT). All tests were performed from fresh 
samples, except protein carbonyls, which were frozen. 
Participants attended two testing sessions (baseline and post-treatment) held in laboratories optimised 
for the collection of psychometric data at Swinburne University of Technology. The duration of the 
sessions was 1.5 h and participants were asked to refrain from ingesting caffeine for three hours 
beforehand. Testing sessions were conducted for each participant individually in the following order: 
informed consent, demographic information, MMSE, blood pressures, height and weight, and 
computerized cognitive tasks. Upon finishing testing, the participants were provided with a referral for 
blood testing and instructions to fast overnight and attend the blood collection centre early in the morning 
the following day or as early as possible thereafter. Participants began supplementation on the day 
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following blood testing and did not take supplements on return testing days, ensuring that only chronic 
effects of the supplements were measured, that is, acute effects were not observed. 
2.5. Statistical Analysis 
Data analysis was performed using IBM SPSS 20. Women’s and Men’s groups were analysed 
separately. Univariate analysis of covariance (ANCOVA) was used to determine the effects of 
multivitamin supplementation on cognitive task performance and blood biomarkers. For each test,  
the post-treatment result was entered as the dependent variable, the baseline result entered as the 
covariate, and treatment group was entered as a fixed factor. 
Data was initially screened to ensure it met the assumptions for ANCOVA including normality and 
homogeneity of variance. The assumptions were met except for the distribution of CRP, which was  
highly positively skewed. A logarithmic transformation was applied (log10(x)), which improved the 
distribution. To avoid undue distortion of the data, values more than three standard deviations from the 
mean were not included in the analysis  
Significance levels were set at p < 0.05 however results with significance levels p < 0.10 are also 
noted, to acknowledge any non-significant trends in the data. There were three primary outcome measures 
(Spatial Working Memory, Contextual Memory and Stroop Interference tasks) and adjustments were 
made to correct for multiple comparisons. Significance was calculated as 0.05/3 = 0.016. 
3. Results 
Participant numbers at recruitment, randomisation and follow up are shown in Figure 1.  
The multivitamin and placebo groups were well matched on demographic variables as shown in  
Table 2. Independent t-tests indicated that there were no significant differences between the group means 
for age, years of education, or body mass index (BMI) at baseline (p > 0.05). Mean compliance was 
95.8% for women and men, which was confirmed by counting remaining tablets at follow up. 
Table 2. Participant characteristics at baseline. 
Characteristic 
Placebo Multivitamin 
M (SD) Range M (SD) Range p 
Males 
Age—years 59.1 (2.3) 55–65 60.2 (3.2) 55–65 0.214 
Education—years 16.5 (3.8) 11–27 16.0 (3.9) 11–23 0.602 
BMI—kg/m2 26.8 (2.9) 21.4–32.3 26.8 (6.2) 19.0–49.2 0.138 
Females 
Age—years 60.1 (3.4) 54–65 60.2 (3.2) 55–65 0.818 
Education—years 14.7 (3.8) 9–24 16.0 (3.9) 11–23 0.163 
BMI—kg/m2 26.3 (4.4) 18.5–36.5 26.8 (6.2) 19.0–49.1 0.717 
p-Values are shown for independent groups t-tests. 
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Figure 1. Flowchart of participant involvement. 
3.1. Cognitive Test Results—Women’s and Men’s Formulas 
Mean accuracy and response time scores for the cognitive tests are presented in Table 3. ANCOVAs 
revealed no effect of supplementation on cognitive task performance for the primary outcome measures, 
Spatial Working Memory, Contextual Memory and Stroop Interference. Therefore the hypothesis that 
these tasks would improve with multivitamin supplementation was not supported. There were no 
significant effects observed on any of the other cognitive measures. A trend for a treatment effect was 
observed for Choice Response Time in the Men’s group (p = 0.053), however this was not corrected for 
multiple comparisons and may be a chance finding. 
3.2. Blood Test Results—Women’s Formula 
Blood tests results for baseline and post-treatment are presented in Table 4. There was a significant 
treatment effect on vitamin B6 (F(1,48) = 55.5, p < 0.001 partial η2 = 0.536), with substantial increases 
in vitamin B6 for women supplemented with the multivitamin, compared with only a very small  
change in those taking placebo. There was also a significant treatment effect for vitamin B12  
(F(1,56) = 30.5, p < 0.001 partial η2 = 0.352), with an increase in B12 in the multivitamin group compared 
with no change in the placebo group. 
 
 
 
Assessed for eligibility  
(female n=  162) 
(male n = 84) 
Excluded  
(female n = 94, male n = 36) 
 
Analysed  (female n = 31, male n = 20) 
Placebo  
Allocated to, and received intervention  
(female n = 35, male n = 21) 
 
Multivitamin 
Allocated to, and received intervention 
(female n = 33, male n = 21) 
 
Analysed  (female n = 31, male = 21 ) 
 
Allocation 
Analysis 
Randomized 
(female n = 68, male n = 48) 
 (female n= 68, male n = 48)  
) 
Multivitamin 
Failed health screen (male n = 2) 
 
Placebo  
Failed health screen (male n = 3) 
Failed MMSE (male n = 1) 
 
 
Withdrew from trial: 
Went interstate/ abroad  
(female n = 2) 
Personal reasons (female n = 
2, male = 1) 
 
Withdrew from trial: 
Went interstate/abroad (female n = 1) 
Commenced excluded medication 
(female n = 1) 
Follow-Up 
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Table 3. Cognitive tests: Means and standard deviations for accuracy (%) and response  
time (ms). No significant effects of supplementation were observed. 
  
Females Males 
Baseline Post 
n 
Baseline Post 
n 
M (SD) M (SD) M (SD) M (SD) 
Spatial Mem., % 
PL 67.1 (13.8) 70.5 (10.6) 30 78.1 (9.9) 81.5 (9.2) 16 
MV 68.7 (13.2) 71.4 (13.3) 26 74.9 (16.1) 77.0 (15.7) 21 
Spatial Mem., ms 
PL 1200 (190) 1132 (127) 30 1023 (136) 996 (115) 16 
MV 1146 (166) 1099 (161) 26 1018 (181) 975 (183) 21 
Contextual, % 
PL 74.3 (17) 73.2 (11.7) 28 69.7 (13.0) 63.8 (12.5) 16 
MV 78.5 (13) 71.1 (13.0) 27 73.4 (17.7) 64.2 (16.9) 19 
Contextual, ms 
PL 1130 (157) 1081 (135) 29 1069 (131) 1082 (116) 16 
MV 1070 (123) 1073 (139) 27 1077 (135) 1061 (168) 19 
Stroop Interfere., ms 
PL 205 (134) 217 (142) 27 220 (207) 152 (109) 15 
MV 187 (135) 188 (139) 23 121 (94) 132 (80) 17 
Stroop Congruent, ms 
PL 775 (91.6) 784 (88) 29 746 (81) 780 (95) 16 
MV 776 (109) 745 (93) 27 743 (99) 726 (102) 21 
Stroop Incong., % 
PL 94.1 (6.2) 93.7 (9.7) 28 91.5 (15.3) 93.2 (7.6) 15 
MV 94.0 (11.4) 94.9 (6.0) 23 97.8 (3.4) 97.5 (4.2) 17 
Stroop Incong., ms 
PL 979 (148) 1000 (140) 28 970 (165) 938 (106) 15 
MV 941 (185) 919 (177) 23 851 (127) 854 (99) 17 
Simple RT, ms 
PL 278 (27.1) 274 (33) 27 262 (32) 257 (27) 17 
MV 276 (26.8) 272 (29) 25 260 (24) 258 (17) 20 
Choice RT, ms 
PL 491 (61) 485 (58) 27 462 (42) 488 (63) 17 
MV 499 (66) 501 (65) 27 467 (56) 457 (50) 20 
Immed. Recog., % 
PL 67.4 (11.7) 76.4 (9.0) 28 70.7 (12.0) 79.8 (7.6) 15 
MV 70.3 (13.0) 78.2 (8.0) 24 67.0 (12.2) 76.7 (8.7) 20 
Immed. Recog., ms 
PL 1151 (161) 1087 (133) 28 1129 (174) 1095 (160) 15 
MV 1084 (102) 1054 (127) 24 1144 (153) 1060 (179) 20 
Delayed Recog., % 
PL 68.0 (8.7) 75.2 (10.4) 28 66.0 (14.3) 70.5 (7.6) 14 
MV 71.2 (9.4) 73.6 (12.3) 26 69.0 (10.0) 70.7 (14.0) 20 
Delayed Recog., ms 
PL 1064 (141) 1020 (126) 28 1123 (162) 1081 (155) 14 
MV 1077 (128) 1023 (148) 26 1073 (95) 1014 (147) 19 
MV = multivitamin, PL = placebo. 
There was a significant treatment effect for homocysteine (F(1,56) = 6.73, p = 0.012, partial  
η2 = 0.107), however post-hoc t-tests indicated that there was increased homocysteine in the placebo 
group (t(30) = −2.65, p = 0.013) rather than a decrease in the multivitamin group, which was not 
significant (t(27) = 0.705, p = 0.487). 
Analysis of the transformed data for CRP revealed a reduction with multivitamin supplementation 
compared with placebo (F(1,51) = 8.60, p = 0.005, partial η2 = 0.152). There were no significant 
treatment effects observed for fibrinogen, protein carbonyls, or for any of the lipid measures in the 
Women’s group.  
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Table 4. Blood test results for women and men at baseline and post-treatment for placebo 
and multivitamin groups. 
Test Units  
Females Males 
Baseline Post-Treatment 
n 
Baseline Post-Treatment 
n 
M (SD) M (SD) M (SD) M (SD) 
Homocysteine, µmol/L 
PL 13.0 (2.9) 14.4 (3.9) 31 ‡ 15.5 (3.9) 16.2 (3.2) 17 † 
MV 12.9 (3.0) 12.6 (2.5) 28 15.1 (3.4) 13.7 (2.8) 21 
Vitamin B12, pmol/L 
PL 300 (78) 298 (91) 31 * 284 (100) 249 (84) 15 * 
MV 300 (103) 435 (143) 28 265 (63) 342 (120) 19 
Vitamin B6, nmol/L 
PL 88 (28) 118 (92) 28 * 151 (120) 160 (155) 13 * 
MV 104 (53) 467 (215) 23 121 (89) 335 (134) 15 
Folate, nmol/L 
PL 744 (290) 800 (228) 30 601 (187) 614 (156) 17 
MV 922 (180) 933 (309) 28 683 (298) 793 (303) 19 
CRP, mg/L 
PL 1.9 (2.2) 1.8 (2.1) 27 † 1.4 (1.5) 0.9 (0.9) 15 
MV 1.9 (2.5) 1.1 (1.2) 24 1.9 (1.7) 1.1 (0.8) 20 
Fibrinogen, g/L 
PL 3.1 (0.3) 3.0 (0.4) 30 3.0 (0.6) 3.1 (0.3) 14 
MV 3.0 (0.5) 3.0 (0.5) 26 2.9 (0.4) 2.9 (0.5) 20 
Prot Carbonyl, mol/mL 
PL 19.6 (7.1) 17.6 (3.5) 24 19.1 (5.2) 19.4 (4.5) 15 
MV 18.2 (7.05) 19.0 (5.1) 24 20.5 (5.1) 16.4 (4.6) 15 
Total Chol, mmol/L 
PL 6.0 (1.1) 5.8 (0.9) 31 5.6 (0.9) 5.7 (1.1) 17 
MV 5.7 (0.8) 5.8 (0.8) 29 5.6 (0.7) 5.3 (0.9) 21 
HDL, mmol/L 
PL 1.80 (0.40) 1.88 (0.48) 31 1.54 (0.30) 1.52 (0.36) 17 
MV 1.90 (0.38) 2.07 (0.56) 29 1.51 (0.42) 1.46 (0.39) 20 
LDL, mmol/L 
PL 3.70 (0.97) 3.40 (1.05) 31 3.42 (0.67) 3.44 (0.79) 17 ‡ 
MV 3.37 (0.66) 3.11 (0.96) 29 3.45 (0.59) 3.06 (0.89) 20 
Triglyceride, mmol/L 
PL 1.2 (0.5) 1.2 (0.6) 31 1.2 (0.5) 1.4 (0.6) 16 
MV 1.0 (0.4) 1.1 (0.4) 28 1.3 (0.5) 1.4 (0.6) 21 
LDL/HDL ratio 
PL 2.2 (0.7) 2.1 (0.7) 31 2.3 (0.6) 2.2 (0.7) 17 
MV 1.8 (0.5) 1.8 (0.5) 29 2.5 (0.7) 2.3 (0.5) 21 
Chol/HDL ratio 
PL 3.5 (0.9) 3.4 (0.8) 31 3.7 (0.7) 3.8 (0.8) 17 ‡ 
MV 3.1 (0.6) 3.1 (0.6) 29 4.0 (0.9) 3.8 (0.7) 21 
AST, U/L 
PL 23.0 (5.7) 21.3 (5.3) 29 * 24.2 (6.0) 24.0 (7.1) 16 
MV 21.4 (45.0) 26.2 (9.7) 29 23.1 (6.2) 25.0 (5.9) 21 
ALT, U/L 
PL 22.9 (10.1) 20.9 (9.1) 29 * 27.5 (12.2) 27.6 (9.4) 16 
MV 18.1 (4.0) 22.9 (5.4) 27 25.6 (7.9) 30.5 (9.9) 21 
MV = multivitamin, PL = placebo; * p < 0.001; † p < 0.01; ‡ p < 0.05 for the effect of treatment at  
follow up, controlling for baseline; CRP—high sensitivity C-reactive protein; AST—aspartate transaminase; 
ALT—alanine transaminase. 
Treatment effects were observed for AST (F(1,56) = 22.84, p < 0.001, partial η2 = 0.290) and ALT 
(F(1,54) = 24.316, p < 0.001, partial η2 = 0.310) which both increased with supplementation.  
Although significant, the changes remained within the provided reference ranges: AST < 41 U/L and 
ALT < 51 U/L (Table 4). 
  
Nutrients 2015, 7 3806 
 
 
3.3. Blood Test Results—Men’s Formula 
Multivitamin supplementation increased vitamin B6 levels (F(1,25) = 23.6, p < 0.001 partial  
η2 = 0.486) and vitamin B12 levels (F(1,31) = 12.9, p = 0.001 partial η2 = 0.295) compared with placebo. 
There was a treatment effect for homocysteine (F(1,35) = 8.42, p = 0.006, partial η2 = 0.194), with a 
decrease in homocysteine in the multivitamin group and an increase in the placebo group. Paired samples 
t-tests indicated that the decrease in the multivitamin group approached significance (t(20) = 1.949,  
p = 0.066), whereas the increase in the placebo group was not significant (p = 0.308). There was no 
treatment effect for fibrinogen. There was no treatment effect for CRP, after logarithmic transformation. 
There was a trend for a reduction in protein carbonyls after supplementation with the multivitamin 
compared with placebo (F(1,28) = 3.491, p = 0.072, partial η2 = 0.111). This reflected a 20% reduction 
in protein carbonyls in men taking the multivitamin compared with only a very small change in the 
placebo group. Post-hoc t-tests indicated that the change in the multivitamin group was significant  
(t(14) = 2.59, p = 0.021), whereas the change in the placebo group was not. 
Supplementation with the Men’s formula had significant effects on some lipid measures. There was 
a significant treatment effect for LDL (F(1,35) = 5.14, p = 0.030, partial η2 = 0.131), and a marginal 
effect for total cholesterol (F(1,35) = 3.30, p = 0.078, partial η2 = 0.086). These changes were  
reflected in cholesterol ratios. The LDL/HDL ratio decreased only in the multivitamin group after 
supplementation (F(1,35) = 4.40, p = 0.043, partial η2 = 0.112). Similarly, there was a trend for a 
reduction in the cholesterol/HDL ratio (F(1,35) = 3.94, p = 0.055, partial η2 = 0.101). There were no 
significant changes in AST or ALT. 
4. Discussion 
The present investigation found no effect of 16-weeks multivitamin, mineral and herbal supplements 
on cognitive task performance in healthy women or men aged 55–65 years. Therefore, the hypothesis 
that these primary outcome measures would be improved with supplementation was not supported. 
However, beneficial changes to blood biomarkers were observed. In the Women’s group, vitamin B6 
and vitamin B12 significantly increased after supplementation and the inflammatory marker CRP was 
reduced. Two markers of liver function, ALT and AST, were also increased however these increases 
were small and within levels of normal within-subject variation for these biomarkers [33]. In the Men’s 
group, blood levels of vitamin B6 and vitamin B12 were also significantly increased; homocysteine, total 
cholesterol and LDL were significantly reduced; and there was a trend for a reduction in protein carbonyl 
concentration, a measure of oxidative stress. ALT and AST were not significantly changed in the  
Men’s group. 
The lack of effect observed for cognition is in contrast to two previous studies by our group,  
which found memory improvements in response to multivitamin supplementation, using the same 
computerized cognitive battery. These included one study examining the effects of a multivitamin, 
mineral and herbal combination on older men who were at increased risk of cognitive decline due to 
lifestyle factors including sedentary occupation [22], and another which examined effects in women 
aged 65 plus years with self-reported memory complaints [30]. This last study was in elderly women 
and used the same Women’s 50 plus multivitamin supplement that was used in the present Women’s 
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study. A key difference in the present study is that participants were healthy and were not selected for 
characteristics that increase their risk of cognitive impairment. Furthermore, the previous studies 
included participants who were older than those in the Women’s and Men’s studies reported here.  
This is true for a further two studies of multivitamin supplementation in older adults, which found 
cognitive benefits [23,34]. Thus, the inclusion of participants with poorer health or older age may be an 
important factor in observing cognitive benefits due to supplementation. 
Despite a lack of cognitive effects of the supplements in this study, there were beneficial changes to 
blood biomarkers. This is important because a reduction of risk biomarkers has the potential to protect 
against impairment over the longer term. In particular, inflammatory biomarkers, protein carbonyls and 
homocysteine are of interest. Cognitive decline is associated with increased chronic inflammation, 
oxidative stress and higher levels of homocysteine, and it has been argued that these risk markers are a 
cause of impairment and not just an indicator of it [28,35,36]. Changes to these biomarkers were 
observed differentially in the Women’s and Men’s studies. This may be due to gender differences in 
older adults, or to ingredients that were specific to each formula (Table 1). However, it is important to 
note that all changes were in beneficial directions, with the exception of the very small changes observed 
in ALT and AST in the Women’s group. Changes to ALT and AST are unlikely to be clinically 
significant, since they remained within the reference range; also measurement of these enzymes has been 
shown to be highly variable [33]. 
CRP is a marker of inflammation and has been shown to predict cognitive decline and dementia [37]. 
An effect of supplementation on CRP was observed in the Women’s group but not the Men’s group. 
This echoes findings from a cross-sectional study, which found that use of multivitamins was associated 
with lower CRP in women, whereas there was no such association in men [38]. The authors suggested 
that supplements may interact with gender-specific factors to produce a reduction in CRP. Gender 
differences are observed in population CRP levels; a recent report indicated that more women had 
elevated CRP than men (32% vs. 20%), however in women it was not associated with as high a risk of 
mortality [39]. 
A reduction in homocysteine was only observed in the Men’s group. The level of homocysteine 
reduction achieved in the Men’s study was a moderate 9.3%, substantially less than the 25% reduction 
that has previously been observed with B-vitamin supplementation [40], and less than the 12.5% reduction 
observed in our previous multivitamin study [22]. In the Vitacog study, participants with mild cognitive 
impairment supplemented for two years with B-vitamin supplementation and a 30% reduction in 
homocysteine was observed, with a concurrent slowing of cognitive decline in the treatment group; the 
higher dose and longer supplementation period might be necessary to observe changes [41]. 
Homocysteine is particularly sensitive to folate levels, folate being necessary for the conversion of 
homocysteine to methionine [28]. Therefore the poor response in the present study could be a result of 
folate malabsorption, which is not uncommon in older adults [42]. 
There was a 20% reduction in protein carbonyls in the Men’s group only. Although this effect only 
approached statistical significance, it is notable due to the size of the reduction. Protein carbonyls have 
previously been demonstrated to be sensitive to supplementation with combinations of vitamins 
including multivitamins [43,44]. A further study demonstrated protein carbonyl reduction in older adults 
after six months of vitamin E supplementation [19]. The change in protein carbonyls suggests that the 
antioxidant vitamins (or other herbal ingredients with antioxidant properties) reduced oxidative stress 
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levels in the Men’s group only. Baseline protein carbonyl levels were higher in the men than in the 
women, perhaps allowing for a stronger effect of supplementation. Increased oxidative stress is thought 
to contribute to cognitive decline as well as neurodegenerative diseases such as Alzheimer’s  
disease [18]. Therefore a reduction in oxidative stress may improve cognitive outcomes in the elderly. 
The Men’s study also observed improvements in the lipid profile. Improvements to the lipid  
profile have previously been observed after supplementation with antioxidant vitamins [45] and 
multivitamins [46]. A recent review examined the effects of dietary interventions and supplements on 
the lipid profile [47]. The authors concluded there was no evidence for an effect of vitamin C, chromium 
or tocotrienols in cholesterol reduction, however they determined that there was evidence for other food 
components, such as soy protein and phytosterols. Also, green tea, red wine, and red yeast rice extract 
were considered to be potentially effective. Although these phytonutrients were not included in the 
present supplements, the Women’s and Men’s formulas contained many plant extracts that also contain 
flavonoid compounds. However, research regarding supplements and the lipid profile is limited and 
further research is required to substantiate the present findings. 
5. Conclusions 
In summary, although the changes observed in the blood markers were small, they occurred over a 
relatively short time span and longer term benefits of supplementation may have a greater impact. 
Further research is therefore warranted to elucidate the role of nutritional supplements in cognitive aging. 
This study demonstrates the importance of assessing risk markers concurrently with cognitive tasks, 
because beneficial changes to risk factors may be crucial for cognitive protection during aging. 
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